Clinical Trial Update: Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial update of erlotinib and sorafenib in progressive or recurrent glioblastoma multiforme; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Giant Cell Glioblastoma
• Glioblastoma
• Gliosarcoma

Drugs mentioned

• Nexavar (Sorafenib)
• Tarceva (erlotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 2 | Status: COMPLETED | Results posted: 2016-04-27